Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis
ConditionBeta Blocker Toxicity
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age50+
SponsorSherief Abd-Elsalam
About this trial
Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis
Eligibility criteria
Qualifiers
• Male & female osteoporotic patient aged ≥ 50 years
Hypertensive & normotensive patients
BMD T-score ≥ 2.5 or more SD below peak bone mass
Disqualifiers
Angiotensin converting enzyme inhibitor (ACEI) or Angiotensin receptor blockers (ARBs), Thiazide diuretic, Nitrates, Spironolactone, Statins.
Trial design
Treatments tested in this trial
- nonselective beta blocker
- cardio-selective beta blocker group
- alendronate sodium
Treatment groups
50 Participants
are divided into 3 treatment groupsSponsors and collaborators
Sherief Abd-Elsalam
Lead sponsor
Tanta University
Sponsor institution
Source ClinicalTrials.gov